Posted by AGORACOM-JC
at 8:00 PM on Sunday, April 12th, 2020
Dear AGORACOM Members, we hope this message finds your families well. We also want to wish Happy Easter and Happy Passover to those that are celebrating.
During this turbulent time, our job now more than ever is to bring you the small cap companies that are actually thriving in order to help you discover your next great company. Thanks to our focus on quality over quantity, AGORACOM clients have been operating exceedingly well and we are very happy to provide you with the following highlights over the last 10 days (in reverse chronological order):
* Empower Clinics (CBDT:CSE) Up 55% On 4.5M Shares Traded – Clinic Patient Visits Up 478% In Q1 (NEWS + VIDEO)
* BetterU Education (BTRU:TSXV) UP 37% On 1M Shares Traded – Closes Deal With USA Paramount For Enterprise Skills Development (NEWS + VIDEO)
* Hollister Biosciences (HOLL:CSE) Up 60% on 4M Shares – Acquisition Adds $16.4M Rev / $2.5M EBITDA (NEWS + VIDEO)
* New Age Metals (NAM:TSXV) 2.9M Ounces Of Palladium Equivalent Is Why Eric Sprott Owns 18.5% (VIDEO)
* Mota Ventures (MOTA:CSE) Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line (NEWSÂ + VIDEO)
* Primo Nutraceuticals (PRMO:CSE) Up 100% On 2.6M Shares – Signs Acquisition LOI with Celebrity brand Beauty Kitchen (NEWS)
* Datametrex A.I. (DM:TSXV) Hired By US Government Agencies On COVID-19 / Coronavirus Fake News and Disinformation (NEWSÂ + VIDEO)
* PyroGenesis (PYR:TSXV) Receives $550K Under an Exclusive Agreement with a US Tunneling Company (NEWS)
We know that most of you have seen most of these headlines on our front page – but make sure to never miss a timely piece of news by also adding us into your social media streams on Twitter and Facebook.
Finally, look for some big news and changes coming to AGORACOM in the next 60 days. We are going to be bigger and better than ever!
Posted by AGORACOM-JC
at 5:52 PM on Thursday, April 9th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More
Where is the CBD Market Headed?
After hemp was legalized for growth and cultivation with the passing of new legislation in 2018, the CBD market erupted with new products and companies looking to take advantage of the new space
As of 2019, CBD sales increased by around 133%, to the tune of over $1 billion. That’s right; one billion. The market has plenty of consumer demand to back it up, and Americans are loving their CBD
With the last few years’ success in the CBD industry, new investors, everyday people, and seasoned investors alike are working to get their hands into one of the fastest-growing markets in the US. The CBD space is full of new providers and products, and new ones are arising each year.
As the research receives more and more funding, we’re learning all kinds of new information about CBD and its effects on the body and mind; and not much of that information is negative.
With so much demand for CBD oil and other products, it’s no surprise that people are looking to get rich by investing in the industry. But there’s still the question of whether or not it’s a good idea to invest in CBD. Let’s take a closer look at the industry, so you can decide whether or not investing in it is the right move for you.
CBD’s Benefits and Popularity
For decades, the Cannabis plant, from which CBD is derived, was outlawed, shamed, and viewed as an addictive and dangerous drug. This is mostly because THC is also derived from Cannabis, which causes the “high†that comes with smoking marijuana or ingesting THC-infused oils and edibles.
CBD is an entirely different cannabinoid, and both CBD and THC are just two of many cannabinoids found in the Cannabis plant. Each cannabinoid interacts with the body’s cannabinoid receptors in a different way, but it would take another article entirely to explain them all.
The bottom line? CBD doesn’t get you high, and industrial hemp must contain less than 0.3% THC to even be legally grown or cultivated.
CBD has been found to offer many benefits to humans and pets alike; among these are:
Pain relief
Anti-inflammatory properties
Counteracts the effects of THC
Useful in addiction recovery
Managing anxiety disorders and stress
Calming effects on the brain
Increase focus and concentration
The benefits of CBD products far outweigh the minor side effects, and preliminary research has yielded promising results for the future of CBD. If you want to buy CBD to give it a try, you’ve chosen the right time to start! There are hundreds of varieties available, but not all CBD is created equal. Quality Matters in CBD
If you’re thinking of investing in the CBD space, you’ll want to put your money towards a product that exceeds others in terms of quality. The higher the quality of the CBD extract, the more potent it is.
Lower-quality extracts aren’t as effective, and if the producer is using imported hemp, you run the risk of contaminating your CBD with pesticides and other chemicals from foreign countries. The US has some strict guidelines on growing hemp, and the top providers in the industry use only organically-grown domestic hemp to extract their CBD.
The Market So Far
After hemp was legalized for growth and cultivation with the passing of new legislation in 2018, the CBD market erupted with new products and companies looking to take advantage of the new space. As of 2019, CBD sales increased by around 133%, to the tune of over $1 billion. That’s right; one billion. The market has plenty of consumer demand to back it up, and Americans are loving their CBD.
Some estimates put the market at around $20 billion by 2022, but more conservative estimates put it somewhere around half that. It’s estimated that by 2024, the market will be worth $10 billion, and that’s not something investors can ignore.
The demand for CBD products only continues to increase as the years go by, so at this point, the only way to know for sure where CBD is headed is to wait and see.
That being said, the market shows potential for growth and continues to gain traction as more and more people try and love CBD products. This makes for an excellent investment opportunity if you know what you’re doing and where to put your money.
Among specialized dispensaries, even general retailers are starting to carry CBD. You may have noticed your local grocery stores, department stores, and even convenience stores carrying CBD oil and other CBD products.
This surge in CBD availability does present an issue, however; the producers are struggling to keep up.
The Quick-Buck Types
As with any industry, there are those looking to make a quick buck by ignoring quality standards and putting out a sub-par product just to get it on the shelves and into the hands of paying customers.
With little regulation on CBD products from government agencies, the standards in the industry are generally set by the top providers, and can’t exactly be enforced.
This leads to general flooding of the market with sub-par products, and many of those “off brands†end up on store shelves as retailers try to get their hand in the CBD market. Many CBD providers are working very hard to ensure their products meet certain standards, and those are the companies you’ll want to keep your eye on.
Where To Next?
The market seems to only be headed upward as time passes. With more money for research and much less stigma surrounding CBD and cannabis, there is the potential for massive growth as the public slowly shifts its opinion on the plant itself. With projections in the billions of dollars for the future, it’s safe to say that this market has a bright future ahead of it.
Not to mention, the better we understand CBD, the better it can be marketed. We’ve already found dozens of incredible benefits for the human body, and we’re sure to find more as our understanding of CBD evolves. We just have to be patient and wait for the research!
In the meantime, the market is flourishing and is expected to flourish well into the 2020 decade. If you’re looking to invest your money in a market that can offer significant ROI and stability, CBD might just be it. Always consult with an expert first, though. You wouldn’t want to put your money into the wrong startup!
Posted by AGORACOM-JC
at 6:00 PM on Wednesday, April 8th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million In revenue and $CDN 2.48 million in EBITDA. FIND OUT MORE
CBD Edibles Market to Exhibit an Astonishing CAGR of 24.30%
Data Bridge Market Research analyses the market to account to USD 5160 million by 2027 growing at a CAGR of 24.30% in the forecast period
Rising global healthcare spending is expected to enhance the market growth
By Data Bridge Market Research
The CBD Edibles Market report comprehensively studies market definition, market segmentation, competitive analysis and key developments in the market. It comprises of fundamental, secondary and advanced information related to the global status and trend, market size, sales volume, market share, growth, future trends analysis, segment and forecasts from 2020 – 2027. It includes an extensive research on the current conditions of the industry, potential of the market in the present and the future prospects from various angles. Thus, the transparent, reliable and extensive market information of this CBD Edibles report will definitely develop business and improve return on investment (ROI).
Data Bridge Market Research analyses the market to account to USD 5160 million by 2027 growing at a CAGR of 24.30% in the forecast period. Rising global healthcare spending is expected to enhance the market growth.
An Overview of the Impact of COVID-19 on Particular Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
CBD Edibles Market Overview 2020-2027: Some of the factors such as rising production of hemp, increasing awareness about the health advantages of cannabis, rising demand from the healthcare industry, and legalization of cannabis in the various industries is expected to enhance the CBD edibles market in the forecast period of 2020 to 2027. High cost of the CBD products and presence of stringent regulations is expected to hamper the market growth in the mentioned forecast period.
Global CBD Edibles Market Scope and Market Size
CBD edibles market is segmented of the basis of source type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
o Based on source type, the CBD edibles market is bifurcated into hemp and marijuana.
o The application segment of the CBD edibles market is segmented into personal care & cosmetics, pharmaceutical, food & beverage and others.
The Global CBD Edibles Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The market Report also calculate the market size, the report considers the revenue generated from the sales of This Report and technologies by various application segments. The data and the information regarding the CBD Edibles industry are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts.
Global CBD Edibles Industry 2020 Market Research Report is spread across 350 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.
Posted by AGORACOM-JC
at 9:21 AM on Monday, March 30th, 2020
At a time when established Cannabis stocks are struggling due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”. Â
If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door. Â
BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA Â
Hollister has closed their purchase of Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 … and all of that was just from the state of Arizona. Â
In this amazing interview, Venom Founder Jake Cohen discusses Venom’s aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries. Right now, some of you may be thinking, “yeah but everybody thinks they are going to expand” …. but Jake’s words, as well as those of Alex Somjen (President) and Carl Saling (CEO) are backed up by action.  Â
Specifically, a significant chunk of Venom’s acquisition shares kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021. In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers. It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now. Â
If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this great interview with Carl Saling, Alex Somjen and Jacob Cohen.
Posted by AGORACOM-JC
at 7:18 AM on Monday, March 30th, 2020
This highly accretive acquisition strengthens Hollister’s brand portfolio and broadens its distribution footprint across multiple states positioning Hollister to transform into an industry leader in 2020 and beyond
Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million in EBITDA from its product line of cannabis concentrates and cartridges.Â
VANCOUVER, March 30, 2020Â –Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“), a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its transformational acquisition of Venom Extracts (“Venom Extracts“), a leading Arizona cannabis extract brand and one of the state’s largest producers of award-winning medical cannabis distillate and related products (the “Transaction“).
HIGHLY ACCRETIVE $20,000,000 ACQUISITION, ADDING OVER CDN$16.4 MILLION OF 2019 REVENUE
For the year ended December 31, 2019, management of Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million
in EBITDA from its product line of cannabis concentrates and
cartridges. Venom Extract’s management also reports a strong start to
2020 and is anticipating record Q1 revenue.
The all-stock purchase price of approximately CDN$20,000,000
represents a transaction multiple of 1.2x 2019 revenue, with
approximately 70% of the consideration paid upfront and the
approximately 30% balance to be paid upon milestone achievements related
to revenue targets for Venom Extracts, or in any event, on December 31, 2021. After conducting normal course due diligence, the Transaction closed effective March 24, 2020 (the “Closing Date“).
KEY TERMS OF THE TRANSACTION:
Pursuant to the terms of the SEA, the Company has acquired Venom Extracts for consideration of CDN$20,000,145.20 which is to be satisfied by the issuance of 70,390,672 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of Venom Extracts and an additional 29,610,054 common shares (the “Earn-Out Shares“)
to certain former shareholders of Venom Extracts on the earlier of (i)
Venom Extracts reaching certain revenue milestones (detailed below), or
(ii) December 31, 2021.
The Payment Shares and the Earn-Out Shares will be issued at a deemed value of CDN$0.20 per share;
The Payment Shares are subject to certain voluntary hold periods
with 90% of the Payment Shares being subject to hold periods as follows:
15% until May 25, 2020; and an additional 15% every six months until November 25, 2022;
The Earn-Out Shares will be issued on the earlier of (i) December 31, 2021, or (ii) when and if the following milestones have been met:
19,740,036 Earn-Out Shares will be issued when revenue of Venom Extracts reaches CDN$30,000,000 (calculated in accordance with IFRS from January 1, 2020); and
An additional 9,870,018 Earn-Out Shares will be issued when revenue of Venom Extracts reaches CDN$40,000,000 (calculated in accordance with IFRS from January 1, 2020).
“We are extremely pleased to complete this transformational and highly accretive acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences Inc. “Our acquisition of Venom Extracts bolts on substantial revenue and EBITDA to Hollister, while providing Venom Extracts the ability to expand its offering of premium branded product into the California marketplace. Likewise, our acquisition also allows Hollister to introduce its products into the Arizona and Nevada marketplaces through Venom Extracts’ existing distribution channels.”
“This is an exciting acquisition and we are very pleased to announce closing”, shared Jacob Cohen, Founder of Venom Extracts. “This transaction represents the next step in ensuring the future growth of both Hollister and Venom Extracts. We are looking forward to increasing our geographic presence by expanding into the California marketplace through Hollister’s existing platform, and exploring expansion of our existing product portfolio collectively.”
In association with the acquisition, Hollister will not
be assuming any long-term debt, a new control position will be created
and there is no change in management, or the board of directors of Hollister being contemplated at this time.
In connection with the Transaction, the Company issued 6,000,000 common shares (the “Finder Shares“) to an arm’s length third party finder at a deemed price of $0.20
per Finder Share. The Finder Shares are subject to a statutory hold
period of four months and a day from the Closing Date which expires July 25, 2020.
This press release is available on the Company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
None of the securities to be issued pursuant to the Transaction have
been or will be registered under the U.S. Securities Act of 1933, as
amended (the “U.S. Securities Act“), or any state
securities laws, and any securities issued pursuant to the Transaction
are anticipated to be issued in reliance upon available exemptions from
such registration requirements pursuant to Rule 506(b) of Regulation D
and/or Section 4(a)(2) of the U.S. Securities Act and applicable
exemptions under state securities laws. In addition, the securities
issued under an exemption from the registration requirements of the U.S.
Securities Act will be “restricted securities” as defined under Rule
144(a)(3) of the U.S. Securities Act and will contain the appropriate
restrictive legend as required under the U.S. Securities Act.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a diversified cannabis company with
multiple, high-quality products now carried in 220 of Indus Holdings
(CSE: INDS), Hollister’s exclusive
distribution partner’s 600 dispensaries. This level of penetration is
expected to grow as the Company accelerates its seed to shelf, high
margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile on www.sedar.com.
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks, tactical relief, tsx Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Closes Transformational Acquisition of Rapidly Growing Venom Extracts Adding Over $16.4 Million In 2019 Revenue and $2.5 Million in EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 7:36 AM on Tuesday, March 24th, 2020
In the wake of the COVID-19 pandemic, Hollister is using its essential business standing and facility to source and produce hand sanitizer for its local community.
The CEO of Hollister Biosciences Inc, Carl Saling, shared: “The community of Hollister, CA is near and dear to our hearts, and as the first licensed cannabis company in the city of Hollister, CA, I feel that we must do whatever we can to help.
VANCOUVER, March 24, 2020 –Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – through its Hollister Cannabis Co division, is stepping up to manufacture and distribute a few thousand bottles of hand sanitizer to Hollister, CA.
A statewide “shelter at home” mandate has been issued for California,
putting a halt to non-essential manufacturing and delay in
distribution. Cannabis retailers and manufacturers are considered
essential businesses in California. In the wake of the COVID-19 pandemic, Hollister is using its essential business standing and facility to source and produce hand sanitizer for its local community.
Hollister will be giving its first batch of hand sanitizer to the Hollister food bank. Multiple batches of hand sanitizer are expected to be delivered to community organizations over the next few weeks.
The CEO of Hollister Biosciences Inc, Carl Saling, shared: “The community of Hollister, CA is near and dear to our hearts, and as the first licensed cannabis company in the city of Hollister, CA, I feel that we must do whatever we can to help.
It infuriated me seeing companies price gouging much needed items,
such as hand sanitizer. I am all for making money, but not at the
expense of playing on people’s fears during a time of crisis. We just
had to act.
We are going to focus on donating to the facilities that are often
overlooked: the food bank, nursing homes, rehabilitation centers, and
homeless shelters, where some of the most vulnerable are sheltering in
place.
I am calling all business owners to step up in this time of crisis and do whatever you can to help your local community.”
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a California based
vertically integrated cannabis company with a vision to be the
sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister
uses a vertically integrated, high margin model, controlling the whole
process from manufacture to sales to distribution or seed to shelf.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll, along with solvent-free bubble
hash, pre-packaged flower, pre-rolls, tinctures, vape products, and
full-spectrum high CBD pet tinctures. Hollister Cannabis Co.
additionally offers white-labeling manufacturing of cannabis products.
Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com
Posted by AGORACOM-JC
at 7:02 AM on Wednesday, March 11th, 2020
Entered into a letter of intent on March 9th, 2020 to acquire Alphamind Brands
Company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development
All stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister common stock
VANCOUVER, March 11, 2020 – Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company has entered into a letter of intent (the “LOI“) on March 9th, 2020 to acquire Alphamind Brands ( “Alphamind“), a company developing legal mushroom based natural health products and conducting R&D in conjunction with accredited universities to develop psilocybin based compounds for drug development.
The all stock purchase price is anticipated to be CDN$ 1,200,000 with such payment to be made in Hollister
common stock. The stock price will be determined based on the greater
of the 14-day VWAP (Volume Weighted Average Price) subsequent to
announcing the transaction and $0.20. The acquisition is subject to normal course due diligence.
“We are very pleased to have entered into an LOI to complete this very exciting acquisition”, shared Carl Saling,
Founder and CEO of Hollister Biosciences Inc. “It is a fundamental
value of our company to improve the overall health and performance of
our customers through our high-quality products and the health benefits
associated with medicinal mushrooms are tremendous. Not to mention, it
is our continual objective to broaden our product scope and Alphamind,
with its experienced management team, is a perfect foothold for us in
the fast-growing market for medicinal mushrooms and complements our
existing cannabis and hemp-based product offering.”
“I think we have found a great partner in Hollister”, shared Robert Birmingham,
CEO of Alphamind Brands. “We have medicinal mushroom based product
SKU’s ready to ship and R&D is underway to develop an exciting IP
portfolio surrounding psilocybin based pharmaceutical treatments. Being
under the Hollister umbrella will allow us to access
additional markets and leverage their existing manufacturing and
distribution infrastructure and will be a fundamental part of the future
growth of our business.”
In association with the arm’s length transaction, Hollister will not be assuming any long-term debt and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a diversified cannabis company with
multiple, high-quality products now carried in 220 of Indus Holdings
(CSE: INDS), Hollister’s exclusive
distribution partner’s 600 dispensaries. This level of penetration is
expected to grow as the Company accelerates its seed to shelf, high
margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Alphamind Brands is a Canada and US based growth stage
company developing a portfolio of legal mushroom based natural health
products as well as conducting R&D initiatives, led by Dr. Nikos Apostolopoulos,
to explore psilocybin based pharmaceutical treatments. The company’s
“ready to ship” product SKU’s include cordyceps, lion’s mane, chaga and
reishi mushroom based: liquid cordyceps, concentrated mushroom powder,
tea, chocolate. The company’s product SKU’s under development include
syrups, elixirs, cold beverages and nasal spray.
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile on www.sedar.com
Posted by AGORACOM-JC
at 4:48 PM on Friday, March 6th, 2020
This highly accretive acquisition will strengthen Hollister’s brand portfolio and broaden its distribution across multiple states
For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.
VANCOUVER, March 6, 2020 – Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce the Company has entered into a definitive agreement  (the “Agreement“) on March 6th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
On February 25, 2020, the Company first announced a Letter of Intent to acquire Venom, including the following financial figures and terms.
HIGHLY ACCRETIVE $20,000,000 ACQUISITION
For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million
in EBIDTA from its product line of Cannabis Concentrates, P.H.O
Concentrates and Cartridges. 2019 Revenue and EBITDA for Venom Extracts
are as reported by Management. Though Hollister believes the figures to be highly reliable, their audit will be part of the ongoing due diligence before closing.
The all stock purchase price is anticipated to be CDN$ 20,000,000,
with 70% to be paid upfront and 30% to be paid upon milestone
achievements related to revenue targets for Venom. The acquisition is
expected to close by March 31, 2020 subject to normal course due diligence.
KEY TERMS OF THE AGREEMENT:
The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once the share price is established, 70% of the Payment Shares will
be issued upon closing of the transaction, subject to hold periods
The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).
“We are very pleased to have entered into a definitive agreement to complete this transformational acquisition”, shared Carl Saling,
Founder and CEO of Hollister Biosciences, Inc. “Financially, we are
bolting on substantial revenue and EBITDA, while strategically, this
allows for the opportunity to bring Venom into the California marketplace and help scale Hollister’s existing operation. Likewise, it allows for the opportunity to introduce Hollister’s products into the Arizona and Nevada marketplaces to start with.”
“This is an exciting acquisition and we are happy to be taking this critical step toward closing”, shared Jacob Cohen, Founder of Venom Extracts. “This transaction represents the next step in ensuring the future growth of both Hollister and Venom. We are looking forward to increasing the geographic scope of our operation by expanding into the California marketplace through Hollister’s existing platform, as well as, exploring expansion of our existing product scope collectively.”
In association with the acquisition, Hollister will not
be assuming any long-term debt, a new control position will be created
and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.
Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
This press release is available on the Company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a diversified cannabis company with
multiple, high-quality products now carried in 220 of Indus Holdings
(CSE: INDS), Hollister’s exclusive
distribution partner’s 600 dispensaries. This level of penetration is
expected to grow as the Company accelerates its seed to shelf, high
margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com.
Posted by AGORACOM-JC
at 8:12 AM on Tuesday, March 3rd, 2020
Adam Smith is a bad ass Green Beret with nearly 17 years of service to his country …. who put a gun in his mouth when his PTSD simply became too much to handle. Pharma drugs prescribed by doctors were actually making his problems worse and he had nowhere to turn.  Â
More than just a story, watch his 2-minute video within our video interview with him and Hollister Biosciences CEO, Carl Saling. Be prepared. Â
Thankfully, a fellow soldier told him about CBD and Smith experienced firsthand how CBD can help retired and active-duty (military and law enforcement) ease their physical and mental issues – especially those who suffer from PTSD and TBI (Traumatic Brain Injury).  Â
The results were so dramatic that Smith’s new mission was to get CBD into the hands of as many soldiers as possible. He founded Tactical Relief and the rest is history. Tactical Relief creates, promotes and sells the highest quality and “most patriotic” CBD oils in the country.  Â
Yes, it’s a great business with tremendous potential for exponential growth. But profit isn’t driving this partnership between Smith and Carl Saling, who himself became very emotional when he shared his family’s deep military roots …. and struggles with PTSD. Â
As an investor in Hollister, you’ll love what this partnership can do for the company. As a human, you’ll love what this partnership is going to do for retired and active-duty military personnel. As a host, I’ve never been more proud of two guests on AGORACOM. Â
Sit back and be prepared to watch the most powerful interview ever produced by AGORACOM.  Â
Please share this video on your social networks so that military personnel and their families can discover Tactical Relief. Â
30% Of Acquisition Price Paid If Venom Revenues Hit $30,000,000 and $40,000,000 By DEC 31, 2021
Average revenue per gram YTD 2019 $CDN 14 and will continue to increase as vape cartridge mix grows ($CDN 30 per gram)
One Of Arizona’s Largest Producers Of Award-Winning Medical Cannabis Distillate
Acquisition Expected To Close By March 31, 2020 Subject To Due Diligence
An established brand in Arizona for high quality
products in the wholesale and distillate marketplace. Venom is
leveraging its brand and success to aggressively expand into other US
states.
ACQUISITION TERMS
Hollister will acquire Venom Extracts for CDN$20,000,000 via Hollister stock
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once share price is established, 70% of the Payment Shares will be issued upon closing of the transaction
Remaining
30% of the Payment Shares will be issued when and if the following
milestones have been met on or prior to December 31st, 2021
